Experimental Drug is First Targeted Therapy to Improve Survival in Certain High-Risk AML Patients, Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center

Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia (AML), reported Richard Stone, MD, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Ho...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news